Paper26548664
Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S and 7 others. Drug Deliv, 2016. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential. Papers, record 26548664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26548664
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Carriers | Major topic |
| Nanoparticles | Major topic |
| Neoplasms | Major topic |
| Topotecan | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Chemistry, Pharmaceutical | |
| Drug Delivery Systems | |
| Emulsions | |
| Mice | |
| Particle Size |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37760469 | Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37760469 | PubMed |
| 37663396 | Omega-3 fatty acid-based self-microemulsifying drug delivery system (SMEDDS) of pioglitazone: Optimization, in vitro and in vivo studies. | Saudi J Biol Sci | 2023 | https://conductscience.org/library/papers/37663396 | PubMed |
| 37376069 | Robust Inclusion Complex of Topotecan Comprised within a Rhodamine-Labeled β-Cyclodextrin: Competing Proton and Energy Transfer Processes. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37376069 | PubMed |
| 36937194 | The Antitumor Effect of Topotecan Loaded Thiolated Chitosan-Dextran Nanoparticles for Intravitreal Chemotherapy: A Xenograft Retinoblastoma Model. | J Ophthalmic Vis Res | 2023 | https://conductscience.org/library/papers/36937194 | PubMed |
| 36844532 | In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis. | ACS Omega | 2023 | https://conductscience.org/library/papers/36844532 | PubMed |
| 36831009 | Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives. | Biomedicines | 2023 | https://conductscience.org/library/papers/36831009 | PubMed |
| 36612067 | Nanoplatform for the Delivery of Topotecan in the Cancer Milieu: An Appraisal of its Therapeutic Efficacy. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612067 | PubMed |
| 35983007 | A Critical Scrutiny on Liposomal Nanoparticles Drug Carriers as Modelled by Topotecan Encapsulation and Release in Treating Cancer. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/35983007 | PubMed |
| 35812154 | Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines. | Saudi Pharm J | 2022 | https://conductscience.org/library/papers/35812154 | PubMed |
| 35811933 | Impact of Composition and Morphology of Ketoconazole-Loaded Solid Lipid Nanoparticles on Intestinal Permeation and Gastroplus-Based Prediction Studies. | ACS Omega | 2022 | https://conductscience.org/library/papers/35811933 | PubMed |
| 35721949 | Ketoconazole-Loaded Cationic Nanoemulsion: In Vitro-Ex Vivo-In Vivo Evaluations to Control Cutaneous Fungal Infections. | ACS Omega | 2022 | https://conductscience.org/library/papers/35721949 | PubMed |
| 35012125 | Development and Optimization of Acriflavine-Loaded Polycaprolactone Nanoparticles Using Box-Behnken Design for Burn Wound Healing Applications. | Polymers (Basel) | 2021 | https://conductscience.org/library/papers/35012125 | PubMed |
| 32550804 | Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model. | Saudi Pharm J | 2020 | https://conductscience.org/library/papers/32550804 | PubMed |
| 31546717 | Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31546717 | PubMed |
| 29029577 | A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption. | Drug Deliv | 2017 | https://conductscience.org/library/papers/29029577 | PubMed |
| 28671589 | Theranostic Liposome-Nanoparticle Hybrids for Drug Delivery and Bioimaging. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28671589 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26548664
GET https://conductscience.org/api/papers/v1/26548664/authors